Compare Quest Diagnostics Inc (DGX) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nerdwallet Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Nerdwallet Inc trades at $9.74 (market cap $625.17M). The key difference: Quest Diagnostics Inc is far larger — about 40.8× Nerdwallet Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Nerdwallet Inc for 45 Days on average.
| DGX | NRDS | |
|---|---|---|
Market Cap | $25.48B | $625.17M |
Volume | 941,866 | 1,321,316 |
Sector | Health | Media |
52-Week High | $247.45 | $15.93 |
52-Week Low | $173.49 | $7.58 |
Typical Hold Time | 56 Days | 45 Days |
Enterprise Value | $31.23B | $539.47M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
NerdWallet (NRDS) trades at $9.79, up 7.76% with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with revenue growing from $539M in 2022 to $837M in 2025, though Q2 2026 earnings missed expectations. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81, while profitability metrics show ROE of 18.16% and net margin of 7.56%.
The stock presents a compelling growth story with accelerating revenue and improving margins, supported by 66.7% analyst buy ratings. Key risks include competitive pressure in organic search and execution challenges in maintaining earnings momentum. The positive cash flow trend and institutional support suggest potential for continued upside if the company can sustain its growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
